FDA Highlights Programs for Innovators at ACR DSI Summit
The FDA joined the ACR®️ Data Science Summit June 9 to give an update about its Total Product Life Cycle Advisory Program.
Read moreThe Washington State Health Care Authority Health Technology Clinical Committee (HTCC) reviewed balloon angioplasty and stenting for lower extremity peripheral artery disease evidence Nov. 21. ACR® participated in the discussion along with the Society of Interventional Radiology, Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, and the Outpatient Endovascular and Interventional Society. ACR began monitoring this topic in August 2025.
HTCC issued draft findings and a coverage decision that are open for public comment until Dec. 16. The coverage determination is for Endovascular therapy for activity-limiting intermittent claudication and chronic limb-threatening ischemia as a covered benefit with conditions. ACR members who perform these procedures are encouraged to submit feedback. Email comments to shtap@hca.wa.gov.
Final findings and coverage decisions will be published in March. Meeting materials and presentations are on the HTCC website.
For more information or if you have questions, contact Alicia Blakey, ACR Principal Economic Policy Analyst.
FDA Highlights Programs for Innovators at ACR DSI Summit
The FDA joined the ACR®️ Data Science Summit June 9 to give an update about its Total Product Life Cycle Advisory Program.
Read moreLower Fee Now in Effect to File No Surprises Act Disputes
Federal agencies released a final rule that updates the No Surprises Act independent dispute resolution process. The rule lowers the IDR administrative or filing fee from $115 to $15.
Read moreACR Urges Funding for NIH All of Us Program
ACR urges Congress to provide dedicated funding for NIH’s All of Us Research Program, a leader in precision medicine technologies and a valuable tool for researchers.
Read more